This is a $43,590 delivery order contract awarded by the National Human Genome Research Institute (NHGRI) to The Emmes Company LLC, a global clinical research organization. The contract is for clinical research support and regulatory assistance with Investigational New Drug (IND) and Investigational Device Exemption (IDE) submissions related to NHGRI protocols. This task order is part of a larger $4 million Indefinite Delivery/Indefinite Quantity (IDIQ) contract between Emmes and NHGRI for clinical research support and collaboration. The contract has no set-aside designation and runs through June 2026. Emmes has secured numerous prime contracts and subcontracts with various NIH institutes, demonstrating its expertise in supporting complex biomedical research projects, including in areas such as infectious diseases, oncology, and rare diseases.
Generated 12/7/24, 9:40 AM